Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia
Erica K. Barnell(Washington University in St. Louis), Obi L. Griffith(Washington University in St. Louis), Sydney R. Anderson(James S. McDonnell Foundation), Ravi Vij(Washington University in St. Louis), Amanda F. Cashen(Washington University in St. Louis), Malachi Griffith(Washington University in St. Louis), Mary C. Politi(Washington University in St. Louis), Iskra Pusic(Washington University in St. Louis), Zachary L. Skidmore(James S. McDonnell Foundation), David H. Spencer(Washington University in St. Louis), John F. DiPersio(Washington University in St. Louis), Kilannin Krysiak(Washington University in St. Louis), Lukas D. Wartman(MACOM (United States)), Eric J. Duncavage(Washington University in St. Louis), Timothy J. Ley(Washington University in St. Louis), Kenneth F. Newcomer(Washington University in St. Louis), John S. Welch(Washington University in St. Louis), Armin Ghobadi(Washington University in St. Louis), Keith Stockerl‐Goldstein(City Of Hope National Medical Center), Mark A. Schroeder(MACOM (United States)), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Camille N. Abboud(Washington University in St. Louis), Peter Westervelt(MACOM (United States)), Meagan A. Jacoby(MACOM (United States)), Stephen T. Oh(Washington University in St. Louis)
Cited by 9
Related Papers
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k